Tivic Health shares surge 25.08% intraday after securing BARDA meeting for Entolimod's acute radiation syndrome development.

Tivic Health Systems surged 25.08% intraday after announcing it secured a pivotal meeting with the Biomedical Advanced Research and Development Authority (BARDA) to discuss Entolimod’s development for acute radiation syndrome. The meeting, part of BARDA’s Radiological and Nuclear Medical Countermeasures Program, allows Tivic to present clinical data on Entolimod’s radiation injury mitigation potential, manufacturing readiness, and regulatory pathways. The event aligns with Entolimod’s existing FDA Fast Track and Orphan Drug designations, heightening investor speculation about potential government partnerships or funding. This news directly drove the stock’s sharp intraday rally, overshadowing earlier mixed sentiment from quarterly earnings and operational updates.